Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Devasar A"'
Autor:
Khoury, E.G. ∗, Lynch-Kelly, K. †, Fulton-Ward, T. ‡, Heritage, S. §, Devasar, A. ¶, Jones, C.M. §, ||, ∗
Publikováno v:
In Clinical Oncology January 2024 36(1):e51-e60
Autor:
Heritage, S.R., Lynch-Kelly, K. †, Kalvala, J. ‡, Tulloch, R. §, Devasar, A. ¶, Harewood, J. ||, Khoury, E. ∗∗, Abdelwahed, A. ††, Fung, A. ‡‡, Bigogno, C.M. §§, Gray, R. ¶¶, Keshwara, S. ||||, Joseph, P.J.S. ∗∗, Selby, P. ∗∗∗, †††, Tharmalingam, H. ‡‡‡
Publikováno v:
In Clinical Oncology August 2022 34(8):e355-e364
Autor:
Angus Phillips, Nitasha Devasar
Publikováno v:
Logos. 33:5-8
Autor:
Nitasha Devasar
Publikováno v:
Logos. 33:11-19
India is the second-largest book market in the world for English-language content. Indian publishing, predominantly educational and 75 per cent in English, is growing at a compound annual growth rate. Tracing the business’s 75-year journey, this ar
Autor:
S R, Heritage, K, Lynch-Kelly, J, Kalvala, R, Tulloch, A, Devasar, J, Harewood, E, Khoury, A, Abdelwahed, A, Fung, C M, Bigogno, R, Gray, S, Keshwara, P J S, Joseph, P, Selby, H, Tharmalingam
Publikováno v:
Clinical Oncology. 34:e355-e364
The British Oncology Network for Undergraduate Societies (BONUS) surveyed students who attended an oncology revision day to determine their views on the current quantity, quality and type of curriculum-based oncology teaching they have experienced.St
Autor:
Devasar, Nitasha (AUTHOR) nitasha.devasar@gmail.com
Publikováno v:
LOGOS: The Journal of the World Book Community. 2020, Vol. 31 Issue 3, p7-12. 6p.
Autor:
Nitasha Devasar
Publikováno v:
Logos. 31:7-12
Academic publishing must change quickly in response to the COVID-19 pandemic. In India, where publishing has a close and symbiotic relationship with the educational system, it has the means to do so. There is a young population, an aspirational natio
Autor:
Sonam Ansel, Mark Stares, Robert J. Jones, Stefan N. Symeonides, Laura Manson, Anirban Ray-Chaudhuri, Manreet Randhawa, Sarah Slater, Abeera Devasar, Jahangeer Malik, Aravindhan Sundaramurthy, Tony Elliott, Balaji Venugopal
Publikováno v:
Journal of Clinical Oncology. 41:645-645
645 Background: The Keynote 426 trial demonstrated 3-weekly pembrolizumab 200mg (pem3w) plus axi twice daily is effective in aRCC. We previously reported real-world experience of pem6w + axi demonstrating a comparable safety profile to pem3w + axi re
Autor:
Aitzaz Qaisar, Balaji Venugopal, Sonam Ansel, Robert J. Jones, Sarah Slater, Stefan N. Symeonides, Jahangeer Malik, Aravindhan Sundaramurthy, Tony Elliott, Abeera Devasar, Mark Stares, Manreet Randhawa
Publikováno v:
Journal of Clinical Oncology. 41:716-716
716 Background: CRP, a biomarker of systemic inflammation, has been shown to have prognostic value in numerous tumour types, including mRCC. The combination of the immune check inhibitor (ICI), pembro, and vascular endothelial growth factor receptor
Autor:
Devasar, Nitasha (AUTHOR) nitasha.devasar@tandfindia.com
Publikováno v:
LOGOS: The Journal of the World Book Community. 2019, Vol. 30 Issue 1, p7-11. 5p.